Relatlimab
Childhood Brain Tumor
Australian & New Zealand Children's Haematology/Oncology Groupmonoclonal_antibodyPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
3 Active assets in the Childhood Brain Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan Australian & New Zealand Children's Haematology/Oncology Group | Phase 1/2 | CC |
Nivolumab Australian & New Zealand Children's Haematology/Oncology Group | Phase 1/2 | CC |
Paxalisib Australian & New Zealand Children's Haematology/Oncology Group | Phase 1/2 | CC |
Atengenal Burzynski Research Institute | Phase 2 | C |
Astugenal Burzynski Research Institute | Phase 2 | C |
Same molecule, other indications
Relatlimab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →